Pacira Biosciences, Inc. PCRX

BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing R

SASKATOON, Saskatchewan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- PharmaCorp Rx Inc. (TSXV: PCRX) (“PharmaCorp” or the “Corporation”) today announced changes to its Board of Directors, Board committee leadership and Corporate Secretary as the Corporation prepares for its 2026 Annual General and Special Meeting of Security Holders (the “2026 AGSM”). Effective August 31, 2026, Calvin Leroux will step down as a director of PharmaCorp and as Chair of the Corporation’s Corporate Governance and Compensation

In early August 2026, Pacira BioSciences reported positive two-year Phase 1 data for its investigational gene therapy PCRX-201 for moderate-to-severe knee osteoarthritis, showing it was well tolerated with exploratory improvements in pain, stiffness, and function, while also advancing Phase 2 enrollment and confirming a successful scale-up to a commercial-ready manufacturing process. PCRX-201 is the first gene therapy for knee osteoarthritis to pair these kinds of sustained clinical results...

Why Pacira BioSciences Stock Is Back in Focus Pacira BioSciences (PCRX) is drawing fresh attention after publishing two year Phase 1 data for its PCRX-201 gene therapy in knee osteoarthritis, along with recent updates on revenue, profitability, guidance, and manufacturing. See our latest analysis for Pacira BioSciences. The recent PCRX-201 update lands after a sharp 1-day share price return decline of 9.96% and a softer 7-day share price return of 7.79%. Pacira BioSciences still shows a...

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome measures showed improvements out to two years in pain, stiffness, and function across all doses and groups — — Phase 2 ASCEND trial of PCRX-201 in knee osteoarthritis advancing with first topline read out on track for year-end 2026 — BRISBANE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, In

Moby summary of Pacira BioSciences, Inc.'s Q2 2026 earnings call

Pacira BioSciences Inc (PCRX) reports a 6% revenue increase, advances EXPAREL reimbursement, and completes iovera divestiture to sharpen focus on core pipeline.

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform

- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options - BRISBANE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from the Standing Strong: The Impact of Pain on America's Workforce survey, which explor

— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process —— Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — BRISBANE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has successfully transitioned PCRX-201 (ene